{"id":99,"date":"2020-04-09T12:23:35","date_gmt":"2020-04-09T12:23:35","guid":{"rendered":"http:\/\/icdlabs.in\/immune-internal\/?page_id=99"},"modified":"2024-07-08T10:50:14","modified_gmt":"2024-07-08T10:50:14","slug":"home","status":"publish","type":"page","link":"https:\/\/icdlabs.in\/immune-internal\/","title":{"rendered":"Immuneel"},"content":{"rendered":"
\n\n\n
\n
\n
\n
<\/div>\n <\/div>\n \n
\n
\n

Immuneel is bringing breakthrough<\/strong> cancer treatment to India. Affordably.<\/h2>\n
<\/div>\n
\n \n\n\n\n

Cell, gene and immunotherapy are at the frontier of cancer treatment, offering real hope to millions. In the few countries, where cell therapies are available, these are very expensive, and access is limited.<\/p>\n

Immuneel is making cell therapies affordable and accessible in India, for India.<\/p>\n\n\n\n <\/div>\n

\n \n <\/span>\n On a mission for India<\/span>\n <\/a>\n \n \n <\/span>\n Our Approach<\/span>\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section><\/div>\n\n
\n\n\n
\n
\n
\n
\n
\n

\n Using immune cells<\/strong> to fight cancer <\/h3>\n
\n \n\n\n\n

Immuneel is pioneering cell and gene therapies such as Chimeric Antigen Receptor T cell therapy (CAR-T cell therapy) in India. CAR-T cell therapies use genetically modified human immune cells to fight cancer.<\/p>\n

Therapies based on this radical idea are being developed globally and Immuneel is working to make this real in India.<\/p>\n\n\n\n <\/div>\n \n <\/span>\n Cell and gene therapies<\/span>\n <\/a>\n \n <\/span>\n CAR-T cell therapy<\/span>\n <\/a>\n \n <\/span>\n How Living drugs are made<\/span>\n <\/a>\n <\/div>\n <\/div>\n

\n
\n
<\/div>\n <\/div>\n <\/div>\n
\n
<\/div>\n
<\/div>\n <\/div>\n
\n
\n
\n
<\/div>\n \"\"\n <\/div>\n <\/div>\n
\n
<\/div>\n \"\"\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section><\/div>\n\n
\n\n\n
\n
\n \n \n \"\"\n <\/div>\n
\n
\n
<\/div>\n
\n

Ending the wait<\/strong> for millions<\/h3>\n
<\/div>\n <\/div> \n
\n
\n

Immuneel offers hope for cancer patients in India. In spite of a rich talent pool of scientists, researchers, specialist physicians and modern hospitals, India lags in access to new and advanced therapies. Immuneel, through its offerings, aims to address the unmet needs of India\u2019s burgeoning cancer populace.<\/p>\n

Immuneel is well positioned to offer advanced options for care, improve access and drive better patient outcomes.<\/p> <\/div>\n

\n \n <\/span>\n Patients are waiting<\/span>\n <\/a>\n \n <\/span>\n India, a crucible<\/span>\n <\/a>\n <\/div>\n <\/div> \n <\/div>\n <\/div>\n<\/section><\/div>\n\n
\n\n
\n
\n
\n
<\/div>\n
<\/div>\n \n \n \n <\/svg>\n <\/div>\n \n
\n
\n
<\/div>\n
<\/div>\n

Calling<\/strong> for partners, today<\/h3>\n <\/div>\n
\n

Partners are intrinsic to Immuneel\u2019s plans to make a difference. We are collaborating with the world\u2019s best to develop and deliver high quality cell therapies affordably. Our talented team, partners and investors are powering our crusade.<\/p>\n

Join us.<\/p> <\/div>\n <\/div>\n <\/div>\n<\/section> <\/div>\n\n

\n\n
\n
\n
\n
\n

What\u2019s happening?<\/strong><\/h3>\n
<\/div>\n <\/div>\n
\n
\n \n\t\t\t\t\t\t\t

\n \tImmuneel Therapeutics Secures Strategic Investment from Taiba Healthcare to Accelerate Growth<\/strong>

The investment coincides with start of commercialization of Immuneel\u2019s First CAR-T Therapy for Relapsed \/ Refractory Non-Hodgkin\u2019s Lymphoma: First Global CAR-T in India\t\t\t\t\t\t\t<\/p>\n\n <\/div>\n

\n \n <\/span>\n Read More<\/span>\n <\/a>\n \n <\/span>\n See other news<\/span>\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section><\/div>\n\n
\n\n
\n\n
Xth July 2024<\/div> \n
Latest Press Release<\/div>\n
Immuneel Therapeutics Secures Strategic Investment from Taiba Healthcare to Accelerate Growth<\/div>\n
\n \n <\/span>\n \n Read More<\/span>\n <\/a>\n <\/div>\n <\/span><\/section>\n\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-parts\/home-template.php","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-99","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/pages\/99","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/comments?post=99"}],"version-history":[{"count":5,"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/pages\/99\/revisions"}],"predecessor-version":[{"id":1706,"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/pages\/99\/revisions\/1706"}],"wp:attachment":[{"href":"https:\/\/icdlabs.in\/immune-internal\/wp-json\/wp\/v2\/media?parent=99"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}